Abstract

579Background: Integrative Clustering (IntClust) is a breast cancer (BC) classification of 10 different subgroups with distinctive molecular profiles and clinical outcomes (Curtis et al., Nature 20...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
‘Small’ randomised neo-adjuvant chemotherapy trials in breast cancer reporting on pathological response: more harm than good?
H Bonnefoi
Annals of Oncology | VOL. 16
H BonnefoiH Bonnefoi
02 Aug 2005
Abstract PD7-09: Changes in hormone levels (E2, FSH, AMH) and fertility of young women treated with neoadjuvant chemotherapy (CT) for early breast cancer (EBC)
...
Cancer Research | VOL. 78
, et. al. ...
14 Feb 2018
Abstract PO5-17-12: Impact of HER2-low status on axillary response and surgical management after neoadjuvant chemotherapy in early breast cancer
Leonardo Roberto Da Silva ... César Cabello
Cancer Research | VOL. 84
Leonardo Roberto Da Silva, et. al.Leonardo Roberto Da Silva ... César Cabello
02 May 2024
Abstract P2-12-08: Impact of summation dose intensity product on pathologic response in patients receiving neoadjuvant chemotherapy for early breast cancer
Manuel Feisst ... Fabian Riedel
Cancer Research | VOL. 82
Manuel Feisst, et. al.Manuel Feisst ... Fabian Riedel
15 Feb 2022
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes
Cristina Astrid Tentori ... Fabio Ciceri
Journal of Clinical Oncology | VOL. -
Cristina Astrid Tentori, et. al.Cristina Astrid Tentori ... Fabio Ciceri
09 May 2024
Addressing Disability in Cancer Survivors
Rachelle Brick ... Emily S Tonorezos
Journal of Clinical Oncology | VOL. -
Rachelle Brick, et. al.Rachelle Brick ... Emily S Tonorezos
09 May 2024
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study
Susanna Hegewisch-Becker ... Niall C Tebbutt
Journal of Clinical Oncology | VOL. -
Susanna Hegewisch-Becker, et. al.Susanna Hegewisch-Becker ... Niall C Tebbutt
09 May 2024
A pivotal phase 2 single-arm study of glecirasib (JAB-21822) in patients with NSCLC harboring KRAS G12C mutation.
Yuankai Shi ... Zhengbo Song
Journal of Clinical Oncology | VOL. 42
Yuankai Shi, et. al.Yuankai Shi ... Zhengbo Song
30 Apr 2024
View more papers